Journal of Alzheimer s Disease · 2017 · 22 citations · 21 references
MedicineNeurologyNeuroscienceClinical NeuroscienceDementiaDiagnostic ImagingAlzheimer DiseaseBrain ImagingCerebrospinal Fluid BiomarkersCognitive ImpairmentDementia BiomarkersDementia DiagnosisAlzheimer's Disease DiagnosisAmyloid Beta PeptidesAmyloid Pet ImagingBiomarkersCerebrospinal Fluid TauFluorine-18 Fluorodeoxyglucose Positron Emission TomographyMild Cognitive Impairment DiagnosisSensitivity
BACKGROUND: Cerebrospinal fluid (CSF) biomarker studies have shown variable accuracy for diagnosis of Alzheimer's disease (AD); therefore, internal validation is recommended. OBJECTIVE: To investigate the correlation between CSF biomarkers and cerebral 18-Florbetapir positron emission tomography (Amyloid-PET) and calculate their sensitivity and specificity to obtain the optimal clinical cut-off points to diagnose the etiology of cognitive impairment. METHODS: We performed Amyloid-PET scans and CSF biomarker levels analyses in 68 subjects (50 with mild cognitive impairment, 11 with AD dementia, and 7 with non-AD dementia). Visual examination of Amyloid-PET scans was performed. CSF analyses were performed using standard sandwich ELISA. RESULTS: Amyloid-PET was positive in 36 subjects, negative in 26, and inconclusive in 6. Optimal clinical cut-off points for CSF markers were the following: amyloid-β 1-42 (Aβ42) = 629 pg/ml, total tau (t-tau) = 532 pg/ml, phosphorylated tau (p-tau) = 88 pg/ml, and t-tau/Aβ42 ratio = 0.58. T-tau/Aβ42 ratio showed the best sensitivity and specificity (92 and 84%, respectively). T-tau and p-tau CSF levels (r2 = 0.867) followed by the t-tau and t-tau/Aβ42 CSF ratio (r2 = 0.666) showed the strongest inter-marker correlation. Interestingly, subjects with inconclusive Amyloid-PET showed intermediate values for all CSF markers between negative and positive Amyloid-PET groups. CONCLUSIONS: CSF t-tau/Aβ42 ratio appears to be the most accurate AD CSF marker. The presence of intermediate values for CSF markers among the subjects with inconclusive Amyloid-PET suggests the presence of other dementias associated with AD pathology or intermediate phenotypes.
21
Guy M. McKhann, David S. Knopman, Howard Chertkow et al. · Alzheimer s & Dementia · 2011 · 18.8K citations · Full text
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois, Howard Feldman, Claudia Jacova et al. · The Lancet Neurology · 2014 · 3.3K citations · Full text
Thomas G. Beach, Sarah E. Monsell, Leslie E. Phillips et al. · Journal of Neuropathology & Experimental Neurology · 2012 · 1.1K citations · Full text
Aging, Memory, and Mild Cognitive Impairment
Ronald C. Petersen, Emre Kokmen, Stephen C. Waring et al. · International Psychogeriatrics · 1997 · 887 citations · Full text